Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Sava Infond d.o.o.

Sava Infond d.o.o. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 800 shares of the biopharmaceutical company’s stock after acquiring an additional 110 shares during the period. Sava Infond d.o.o.’s holdings in Regeneron Pharmaceuticals were worth $507,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.4%

REGN stock opened at $511.92 on Tuesday. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The company has a market cap of $55.27 billion, a price-to-earnings ratio of 13.03, a PEG ratio of 1.87 and a beta of 0.31. The business has a fifty day simple moving average of $557.15 and a 200-day simple moving average of $638.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals’s revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.69%. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Bank of America lowered their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. The Goldman Sachs Group reduced their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Finally, Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.